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ABSTRACT
A 43-year-old man had a peritoneovenous shunt inserted for the treatment of chylous ascites secondary to myelofibrosis. Despite
being on anticoagulation for superior mesenteric vein thrombosis, he developed shunt dysfunction within two weeks of insertion.
Superior venacavography showed multiple filling defects in the right axillary vein, no filling of the right brachiocephalic and right
subclavian vein, and thrombotic occlusion of the internal jugular veins bilaterally. The shunt was removed 11 days after insertion,
and there was extensive thrombosis of the venous end of the shunt and the compressible pump chamber. Shunt thrombosis is
known to occur but remains a rare complication, with 87% of such obstructions being due to a thrombus at the tip of the venous
end of the shunt. Extensive thrombosis of the shunt (as in the present case) is very rare.
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The insertion of peritoneovenous shunts1 for the treatment
of intractable ascites results in an increase in cardiac output,
plasma volume and an improvement in renal function, with
an enhanced response to diuretics. However, shunt occlu-
sion or malfunction, with recurrence of ascites, are well
described complications of the procedure. We present the
details of a patient who developed the rare complication of
extensive thrombosis of the venous end and compressible
pump chamber of a peritoneovenous shunt inserted for the
treatment of chylous ascites secondary to myelofibrosis.
Case history
A 43-year-old man with refractory chylous ascites requiring
weekly paracentesis was admitted with hypovolaemic acute
kidney injury. He had presented initially six months earlier
with a history of alcoholism (20–50 units/week) and oeso-
phageal varices (grade 2 seen on upper gastrointestinal
endoscopy). Computed tomography had revealed
hepatosplenomegaly, a mass in the porta hepatis compress-
ing the portal vein and superior mesenteric vein thrombosis.
Bone marrow and liver sampling confirmed myelofibrosis
with extramedullary haematopoiesis and he had tested posi-
tive for the Janus kinase 2 mutation (associated with myelo-
proliferative neoplasms). He was anticoagulated, and
treated with hydroxycarbamide and then ruxolitinib with
resultant reduction in splenomegaly. However, accumula-
tion of ascites escalated with subsequent renal impairment.
After optimisation of renal function, an 11.5 Fr Denver®
(peritoneovenous) shunt (CareFusion, Waukegan, IL, US)
was placed under general anaesthesia. The abdominal por-
tion was inserted surgically intraperitoneally between the
liver and costal margin; the venous end was inserted into
the right subclavian vein under fluoroscopic guidance. Anti-
coagulation was continued, and both ascites and electrolyte
disturbance resolved. Unfortunately, in the second postoper-
ative week, the ascitic fluid started to reaccumulate.
The patient’s nutritional needs mandated placement of a
central venous catheter but ultrasonography demonstrated
thrombosis of the axillary vein and complete occlusion of the
right subclavian vein, raising the suspicion of extensive cen-
tral venous occlusion. Superior venacavography showed mul-
tiple filling defects in the right axillary vein, no filling of the
right brachiocephalic and right subclavian vein, and throm-
botic occlusion of the internal jugular veins bilaterally (Fig 1).
Eleven days after insertion, the Denver® shunt was removed
under local anaesthesia, revealing thrombosis extending
from the venous end of the shunt to the compression chamber
(Fig 2). Parenteral nutrition was abandoned because of
venous occlusion while the presence of myelofibrosis pre-
cluded multivisceral transplantation. The patient was trans-
ferred to the palliative care physicians for end-of-life care and
he died three weeks after the removal of the shunt.
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Discussion
The use of a pressure activated one-way valve in a device
to shunt fluid from the peritoneal cavity to the superior
vena cava for the treatment of intractable ascites was
described by LeVeen et al in 1974.1 The shunt facilitates
drainage of ascitic fluid from the high pressure peritoneal
cavity to the low pressure central venous system, and flow
in the shunt is maintained if the difference in pressure
between the high and low pressure ends of the shunt is
30–50mm of water, as occurs with inspiration. The valve
closes when the gradient across the shunt falls below
30mm of water, preventing reflux of blood into the venous
end of the tubing.
The Denver® shunt is one such modification of the origi-
nal design.2 The shunt is primed with saline and the peri-
toneal end is placed in the peritoneal cavity, usually
between the right lobe of the liver and the ribs, with care
being taken to prevent omentum from wrapping around
the tip. The shunt is then tunnelled to the neck subcutane-
ously, with the compressible pump chamber being placed
over the lower ribs to aid manual compression of the
chamber, and the venous end is then inserted into the
superior vena cava via the internal jugular or subclavian
veins under fluoroscopic guidance. Shunts may also be
placed percutaneously.3
Medically intractable ascites secondary to chronic liver
disease is the most common indication for insertion of a
peritoneovenous shunt4 while other indications include
malignant ascites,5 chylous ascites6 and ascites secondary
to portal vein thrombosis or renal disease. Primary shunt
patency averages three months5 and a review of a series of
studies has shown that the perioperative mortality rate can
be as high as 18%, with a 46% survival rate at 21 months
and effective palliation of ascites in 59% of survivors at 18
months.4 When inserted for malignant ascites, mean sur-
vival has been shown to be 3.0 ± 1.7 months, with shunts
providing effective palliation in up to three-quarters of
patients.5
The best results are seen in patients with milder liver
disease and the loss of ascites does not necessarily corre-
late with a functioning shunt.4 Abstinence from alcohol is
associated with hepatic functional recovery and may
decrease renal sodium retention, resulting in shunt occlu-
sion due to low flow.4 Shunt occlusion is the most common
complication, with only 18.6% of shunts remaining func-
tional in survivors at two years.4 Disseminated intravascu-
lar coagulation has also been reported in up to 9% of
patients after shunt insertion5,7,8 and may be caused by
activators found in ascitic fluid, such as tissue factor, which
is a transmembrane surface protein known to initiate
thrombogenesis.9 Coagulopathy and fluid overload may be
preventable by total ascitic fluid drainage at the time of
surgery.4 Perioperative infections with staphylococcal and
Gram-negative organisms can occur, and bacterial
Figure 1 Filling defects are seen in the right brachial and
axillary veins with complete occlusion of the right subclavian
and brachiocephalic veins. Right upper limb venous drainage is
via the thyrocervical trunk and azygos vein. The left axillary,
subclavian and brachiocephalic veins as well as the superior
vena cava are patent.
Figure 2 Denver® shunt showing extensive thrombosis of the
venous end and compressible pump chamber
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peritonitis or septicaemia necessitate shunt removal. Other
complications include shunt fracture, displacement and
leakage.
Shunt thrombosis is known to occur but remains a rare
complication,10,11 with 87% of such obstructions being due
to a thrombus at the tip of the venous end of the shunt.12
Extensive thrombosis of the shunt (as in the present case)
is very rare. Furthermore, in such cases, it has been
reported that cavography disclosed a complete obstruction
of the superior vena cava or one of its branches in 65% of
patients.12
Endovascular approaches to treating central venous
occlusions have been described10 while the use of strepto-
kinase to maintain short-term shunt patency has been
shown to be successful in cases of shunt thrombosis.11 In
the present case, thrombosis of the right brachiocephalic,
subclavian and axillary veins occurred within two weeks of
insertion of Denver® shunt, and extended into the venous
end of the shunt despite anticoagulation. The cause for
extensive venous and shunt thrombosis in this case
remains unexplained although a hypercoagulable state is
often associated with myelofibrosis. This may have been
compounded by the disseminated intravascular coagulop-
athy associated with shunt insertion.5,7,8
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